J45.9 – Bronchial Asthma Unspecified | ICD-10
J45.9 is the ICD-10 code for bronchial asthma, unspecified. It describes a chronic airway disease characterised by recurrent coughing, shortness of breath, and wheezing.
Things worth knowing about "J45.9"
J45.9 is the ICD-10 code for bronchial asthma, unspecified. It describes a chronic airway disease characterised by recurrent coughing, shortness of breath, and wheezing.
What Does the ICD-10 Code J45.9 Mean?
The code J45.9 belongs to the International Classification of Diseases (ICD-10) and stands for bronchial asthma, unspecified. It is used when a diagnosis of asthma has been established but no further subclassification – such as allergic or non-allergic asthma – has been documented. Bronchial asthma is a chronic inflammatory disease of the airways and is one of the most common chronic conditions worldwide.
Causes and Risk Factors
Bronchial asthma results from a combination of genetic predisposition and environmental triggers. The airways of affected individuals are hyperresponsive to a variety of stimuli. Common triggers include:
- Allergens such as house dust mites, pollen, animal dander, or mould
- Air pollution and smoking (active and passive)
- Physical exertion
- Respiratory infections (e.g. viral)
- Cold or dry air
- Certain medications (e.g. aspirin, beta-blockers)
- Psychological stress
Symptoms
The typical symptoms of bronchial asthma often occur in episodes and can vary in severity:
- Wheezing (a whistling or squeaky sound when breathing out)
- Shortness of breath (dyspnoea), especially during exertion or at night
- Persistent, dry cough, often worse at night or early in the morning
- Chest tightness
- Difficulty exhaling
During a severe asthma attack, acute breathlessness may occur, which constitutes a medical emergency.
Diagnosis
The diagnosis of bronchial asthma is based on the medical history, physical examination, and specific lung function tests:
- Spirometry: Measurement of lung function, particularly airflow
- Bronchodilator reversibility test: Demonstrates reversible airway obstruction after inhalation of a bronchodilator
- Peak flow measurement: Assesses maximum airflow speed and monitors disease progression
- Allergy testing: Skin prick or blood tests when allergic asthma is suspected
- Bronchial provocation tests: Controlled induction of bronchoconstriction to confirm the diagnosis
Treatment
The treatment of bronchial asthma aims to control symptoms, prevent attacks, and improve quality of life. It includes:
Pharmacological Treatment
- Reliever medications: Short-acting beta-2 agonists (e.g. salbutamol) for rapid relief of acute symptoms
- Controller medications: Inhaled corticosteroids (ICS) as the cornerstone of maintenance therapy to reduce airway inflammation
- Combination products: ICS with long-acting beta-2 agonists (LABA) for more severe disease
- Biologics: E.g. omalizumab or mepolizumab for severe allergic or eosinophilic asthma
Non-Pharmacological Measures
- Avoidance of known triggers (allergen reduction)
- Breathing physiotherapy and patient education
- Allergen immunotherapy (desensitisation) for allergic asthma
- Regular follow-up appointments with a healthcare professional
Clinical Relevance of Code J45.9
The ICD-10 code J45.9 is used by physicians, hospitals, and health insurers for documentation, billing, and statistical purposes. Unlike more specific codes such as J45.0 (predominantly allergic asthma) or J45.1 (non-allergic asthma), J45.9 is applied when the exact asthma subtype is not specified. Accurate coding is essential for optimal treatment planning and healthcare resource allocation.
References
- Global Initiative for Asthma (GINA): Global Strategy for Asthma Management and Prevention (2023). Available at: https://ginasthma.org
- National Institute for Health and Care Excellence (NICE): Asthma: diagnosis, monitoring and chronic asthma management. NICE Guideline NG80 (2017, updated 2021). Available at: https://www.nice.org.uk/guidance/ng80
- World Health Organization (WHO): Asthma Fact Sheet (2023). Available at: https://www.who.int/news-room/fact-sheets/detail/asthma
Most purchased products
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®The latest entries
3 Posts in this encyclopedia categoryMost read entries
3 Posts in this encyclopedia categoryMagnesiumcarbonat
Calorie content
Cologne list
Related search terms: J45.9